Immunology: investors are tapping into high growth specialty medicines

research_biotech_lab_vial_big

A Feature analyzing how - and why - immunology remains a steady area of investment for big pharma and private investors.

According to the US pharmaceutical trade body  PhRMA, there are more than 800 medicinal products in clinical development to treat chronic diseases. Many of these drugs target immunological disorders which include autoimmune arthritis (81), cutaneous inflammatory conditions (including psoriasis (67) and atopic dermatitis (41) inflammatory bowel disease (58) (including Crohn’s disease (29) and ulcerative colitis (39)), lupus (39), multiple sclerosis (32) and type 1 diabetes (34).

During the last two decades, the therapeutic armamentarium for immunology diseases has been transformed to include broad-spectrum immune modulators and highly specific monoclonals. Large pharma has invested heavily in this field and is now reaping the rewards. In 2021, AbbVie (NYSE: ABBV) secured pole position with total immunology revenues of $25.24 billion, followed by Johnson & Johnson (NYSE: JNJ) and Roche (ROG: SIX) (Figure 1).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology